Russ 2003.

Methods	Study design: parallel RCT Study duration: recruitment not reported Duration of follow‐up: 6 months
Participants	Setting: multicentre (7 centres) Country: Australia Adult recipients of a 1st or 2nd cadaveric or non–HLA identical living donor kidney graft Number: treatment group (33); control group (31) Mean age ± SD (years): treatment group (43.9 ± 12.1); control group (46.9 ± 12.2) Sex (M/F): treatment group (20/13); control group (21/20) Exclusion criteria: PRA > 50%; recipients of re‐grafts who had lost their 1st graft from rejection within the 1st 6 months
Interventions	Treatment group SRL trough levels: 10 to 20 ng/mL (to week 4), 10 to 15 ng/mL (weeks 5 to 12), 8 to 15 ng/mL (to 6 months) TAC trough levels: 3 to 7 ng/mL Control group SRL trough levels: 5 to 10 ng/mL TAC trough levels: 10 to 15 ng/mL (to week 4), 8 to 12 ng/mL (to 6 months) Both groups SRL within 48 h of transplant Steroids
Outcomes	Graft function Incidence of rejection Patient survival at 6 months Graft survival at 6 months
Notes	Part of a Global trial published separately Funding source: Wyeth Australia
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No further data reported after 6 months
Selective reporting (reporting bias)	Low risk	6 month data was reported as specified in methods
Other bias	High risk	Funded by Wyeth